Webinar Humanized Animal Models

Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies

March 29, 2024

Speaker: Luke Yu, MD, Ph.D. Global head of Preclinical Pharmacology, Biocytogen Boston Corp & Biocytogen Pharmaceuticals Atopic Dermatitis is a chronic inflammatory skin condition characterized by redness, cracking, and scaling, often leading to painful sores. While the precise cause of AD remains unclear, a dysfunctional epidermal barrier and dysregulated immune responses (including IL-4, IL-13, IL-25, […]

Read More

Predicting Toxicity of Immuno-Oncology Drug Candidates: Preclinical Platforms to Evaluate Toxicology In Vivo and Ex Vivo

October 25, 2023

Speaker: Jenna Frame, Ph.D. Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Corp Therapeutics targeting the immune system for oncology applications (such as immune checkpoint inhibitors, or ICIs) can in some cases lead to adverse effects in patients, and may affect multiple organ systems and/or cause CRS (cytokine release syndrome). Thus, predicting the safety and […]

Read More

Joint, Lung, and Urinary Disease Models Offered at Biocytogen

May 26, 2023

Speaker: Jenna Frame, Ph.D.  Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Inflammatory disease models are important preclinical research tools to study disease pathogenesis and uncover novel treatments. To directly evaluate the efficacy and safety of therapeutic drug candidates targeting these disorders, we can establish disease in wild-type and/or humanized mouse models. In this webinar, […]

Read More

Inflammatory Disease Modeling for Preclinical Studies

February 17, 2023

Speaker: Rebecca Soto, Ph.D. Scientist II/Associate Manager Content Marketing, Biocytogen Boston Provided a brief overview on molecular mechanisms driving disease progression. Discussed modeling inflammatory diseases in wild-type and humanized mice, including psoriasis, atopic dermatitis, delayed type hypersensitivity, inflammatory bowel disease and experimental autoimmune encephalomyelitis. Evaluated in vivo efficacy of therapeutic agents in preclinical inflammatory disease […]

Read More

Preclinical Models to Investigate NK Cell-Targeted Immunotherapies

September 2, 2022

Speaker: Jenna Frame, Ph.D.  Manager, Scientific Communications & Marketing, Biocytogen Boston Reviewed the mechanisms driving NK cell activity in the context of immuno-oncology, and the types of NK-targeted immunotherapies currently under investigation Introduced experimental models used to evaluate these immunotherapies, including syngeneic models and xenograft models 

Read More

Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery

June 24, 2022

Speaker: John Charpentier, Ph.D, Business Development Manager, Biocytogen Boston Introduced Biocytogen’s highly immunodeficient B-NDG mouse model Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models Described how B-NDG models recapitulate critical aspects of human biology, making them a powerful tool for biomedical research

Read More

Mouse Models to Investigate New Treatments for Inflammatory Disease

January 27, 2022

Speaker: Jenna Frame, Ph.D.  Manager, Scientific Communications & Marketing, Biocytogen Boston Introduced immune system, cytokines, and autoimmune diseases. Reviewed Modeling Inflammatory Diseases in Wild-Type and Humanized Mice, including multiple Sclerosis/EAE, Rheumatoid Arthritis and Colitis/Inflammatory Bowel Disease. Inflammatory & autoimmune diseases have complex etiologies and mechanisms, but can be modeled in mice. We have established protocols […]

Read More

Investigating Inflammatory Disease using Humanized Cytokine Mice

December 2, 2021

Speaker: Clarke Gasper, Ph.D. Senior Business Development Manager, Biocytogen Boston We reviewed the range of cytokines associated with various autoimmune and allergy related diseases. Introduced various humanized cytokine mouse models that can be used in disease modeling. The inflammatory disease models we have developed includes asthma, atopic dermatitis, and psoriasis. Details of some typical readouts […]

Read More

Back to top